EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Evaluation of fatty liver disease self-care applications: a systematic review and evaluation of apps using the mobile application rating scale (MARS).BMC gastroenterology · 2026
   Pooled it
2. Diabetes and NAFLD: A Synergistic Threat to Metabolic Health.Advanced pharmaceutical bulletin · 2025
   Review
3. Potential Applications and Risks of Supranutritional Selenium Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Critical Review.Nutrients · 2025
   Review
4. Metabolic dysfunction-associated steatotic liver disease and omega-6 polyunsaturated fatty acids: Friends or foes.World journal of hepatology · 2025
   Article
5. Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study.International journal of environmental research and public health · 2022
   Article
6. Insulin resistance is related with liver fibrosis in type 2 diabetic patients with non-alcoholic fatty liver disease proven biopsy and Mediterranean diet pattern as a protective factor.Endocrine · 2020
   Article
7. Detection of Early Disease Risk Factors Associated with Metabolic Syndrome: A New Era with the NMR Metabolomics Assessment.Nutrients · 2020
   Review
8. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.Cells · 2020
   Review
9. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.Scientific reports · 2019
   Article
10. Dietary Patterns and Components in Nonalcoholic Fatty Liver Disease (NAFLD): What Key Messages Can Health Care Providers Offer?Nutrients · 2019
    Review
11. Imaging of hepatocellular carcinoma and image guided therapies - how we do it.Cancer imaging : the official publication of the International Cancer Imaging Society · 2017
    Review
12. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome.Visceral medicine · 2016
    Review
13. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.CMAJ open
    Article

Corrections and comments

• Comment on
  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as